Enanta Pharmaceuticals, Inc. - ENTA
About Gravity Analytica
Recent News
- 10.02.2025 - Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- 10.02.2025 - Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- 10.01.2025 - Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
- 10.01.2025 - Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
- 09.30.2025 - Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
- 09.30.2025 - Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
- 09.29.2025 - Enanta Pharmaceuticals RSVHR Study Results Call
- 09.29.2025 - Enanta Pharmaceuticals RSVHR Study Results Call
- 09.29.2025 - Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
- 09.29.2025 - Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults